Anti-SERT-SAP (Cat. #IT-23) utilizes a monoclonal antibody to the fourth extracellular domain of the serotonin re-uptake transporter (SERT). SERT is the major determinant of serotonin inactivation following release at synapses, is the site of action for many tricyclic antidepressants and the SSRIs (serotonin-selective reuptake inhibitors), and is also targeted by a number of psychostimulants including cocaine, methylphenidate, and MDMA ‘ecstasy.’ SERT is produced from a single gene and is expressed in both the CNS and GI system. Decreased serotonergic neurotransmission has been proposed to play a key role in the etiology of depression. Recent findings suggest that SERT might be linked to both neurotic and sexual behavior as well as to obsessive-compulsive disorder (OCD).
ATS has developed a new version of Anti-SERT-SAP and is looking for experienced researchers to test its activity in an in vivo system. If you are interested in testing this new targeted toxin, please contact us with a brief description of your experimental design and how much material you will need to complete it. You will be provided with Anti-SERT-SAP and a control conjugate (Mouse IgG-SAP; Cat. #IT-18) at no charge. In return ATS asks to be able to share an image or visual result from your experiment that will inform other researchers of how the conjugate works.
NOTE: This archived news article contains offers that are no longer active.